BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

This is a dose escalation and dose expansion study to assess the safety and tolerability of BGB-21447 (a B-cell leukemia/lymphoma 2 inhibitor, Bcl-2i) in combination with fulvestrant, with or without BGB-43395 (cyclin-dependent kinase 4 inhibitor, CDK4i), in adults with HR+/HER2- metastatic breast cancer.

NCT Number	NCT06756932
Lead Sponsor	BeOne Medicines
Conditions	Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
Enrollment	120 participants
Start Date	2025-02-04
Primary Completion	2027-07-30 (estimated)
Study Completion	2027-07-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-04